Begins Quoting Large-Scale Building Applications with a Focus on Recurring Revenues and Monetization of Carbon Credits TORONTO, ONTARIO – December 6, 2021 – Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the...
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529) Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2) Adding inflammatory markers along with viral load testing to current Phase 3...
Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infection Meeting response validates CMC package for PD-001 as an oral...
TORONTO, Nov. 23, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
Results of the 4 cancer types where cepharanthine provides exceptional potency and/or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy provides support for next development stage Advancing Cepharanthine (PD-001) to IND-enabling...